| Literature DB >> 31763733 |
Henning Madry1,2, Liang Gao1, Ana Rey-Rico1, Jagadeesh K Venkatesan1, Kathrin Müller-Brandt1, Xiaoyu Cai1, Lars Goebel1,2, Gertrud Schmitt1, Susanne Speicher-Mentges1, David Zurakowski3, Michael D Menger4, Matthias W Laschke4, Magali Cucchiarini1.
Abstract
Advanced biomaterial-guided delivery of gene vectors is an emerging and highly attractive therapeutic solution for targeted articular cartilage repair, allowing for a controlled and minimally invasive delivery of gene vectors in a spatiotemporally precise manner, reducing intra-articular vector spread and possible loss of the therapeutic gene product. As far as it is known, the very first successful in vivo application of such a biomaterial-guided delivery of a potent gene vector in an orthotopic large animal model of cartilage damage is reported here. In detail, an injectable and thermosensitive hydrogel based on poly(ethylene oxide) (PEO)-poly(propylene oxide) (PPO)-PEO poloxamers, capable of controlled release of a therapeutic recombinant adeno-associated virus (rAAV) vector overexpressing the chondrogenic sox9 transcription factor in full-thickness chondral defects, is applied in a clinically relevant minipig model in vivo. These comprehensive analyses of the entire osteochondral unit with multiple standardized evaluation methods indicate that rAAV-FLAG-hsox9/PEO-PPO-PEO hydrogel-augmented microfracture significantly improves cartilage repair with a collagen fiber orientation more similar to the normal cartilage and protects the subchondral bone plate from early bone loss.Entities:
Keywords: biomaterial-guided therapy; cartilage defects; gene therapy; rAAV; tissue engineering
Mesh:
Substances:
Year: 2019 PMID: 31763733 DOI: 10.1002/adma.201906508
Source DB: PubMed Journal: Adv Mater ISSN: 0935-9648 Impact factor: 30.849